Dianthus Therapeutics Inc [NASDAQ: DNTH] traded at a high on Thursday, posting a 2.74 gain after which it closed the day’ session at $19.50.
The results of the trading session contributed to over 180937 shares changing hands. Over the past one week, the price volatility of Dianthus Therapeutics Inc stands at 8.95% while the volatility over the past one month is 11.16%.
The market cap for DNTH stock reached $626.46 million, with 31.12 million shares outstanding and 22.26 million shares in the current float. Compared to the average trading volume of 325.29K shares, DNTH reached a trading volume of 180937 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Dianthus Therapeutics Inc [DNTH]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNTH shares is $52.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNTH stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Dianthus Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 20, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on October 03, 2024, representing the official price target for Dianthus Therapeutics Inc stock. Previously, the target price had yet another raise to $58, while Robert W. Baird analysts kept a Outperform rating on DNTH stock.
The Average True Range (ATR) for Dianthus Therapeutics Inc is set at 1.86, with the Price to Sales ratio for DNTH stock in the period of the last 12 months amounting to 100.39. The Price to Book ratio for the last quarter was 1.72, with the Price to Cash per share for the same quarter was set at 8.57.
How has DNTH stock performed recently?
Dianthus Therapeutics Inc [DNTH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.00. With this latest performance, DNTH shares dropped by -5.29% in over the last four-week period, additionally sinking by -29.19% over the last 6 months – not to mention a drop of -19.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNTH stock in for the last two-week period is set at 53.31, with the RSI for the last a single of trading hit 59.39, and the three-weeks RSI is set at 50.28 for Dianthus Therapeutics Inc [DNTH]. The present Moving Average for the last 50 days of trading for this stock 20.59, while it was recorded at 18.80 for the last single week of trading, and 24.73 for the last 200 days.
Dianthus Therapeutics Inc [DNTH]: Deeper insight into the fundamentals
Dianthus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.22 and a Current Ratio set at 15.22.
Earnings analysis for Dianthus Therapeutics Inc [DNTH]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNTH. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dianthus Therapeutics Inc go to -16.78%.
Insider trade positions for Dianthus Therapeutics Inc [DNTH]
There are presently around $114.20%, or 124.22%% of DNTH stock, in the hands of institutional investors. The top three institutional holders of DNTH stocks are: FMR LLC with ownership of 4.4 million shares, which is approximately 12.8624%. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding 3.01 million shares of the stock with an approximate value of $$77.99 million in DNTH stocks shares; and BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, currently with $$75.5 million in DNTH stock with ownership which is approximately 8.5232%.
